Immunocore (NASDAQ: IMCR) — Perfil da empresa, notícias e dados financeiros
Immunocore is a biotechnology company pioneering immunotherapies, targeting cancer and infectious diseases with innovative therapies.
Immunocore
Immunocore (NASDAQ:IMCR) is a pioneering biotechnology company focused on developing and commercializing a new generation of immunotherapies to improve the lives of patients with cancer and infectious diseases. Its cutting-edge platform leverages T cell receptor (TCR) technology to target and destroy cancer cells in a unique and effective way. The company's flagship project, tebentafusp, targets uveal melanoma, a rare and aggressive form of melanoma. Beyond oncology, Immunocore has an interest in infectious diseases, exemplified by its efforts to combat HIV and hepatitis B. Driven by innovation and the quest for impactful treatments, Immunocore's objective is to advance its pipeline through clinical trials to deliver life-changing therapies to those in need.
Resumo
Operações
Produtos e/ou serviços de Immunocore
- KIMMTRAK (tebentafusp-tebn) for metastatic uveal melanoma, the first T cell receptor therapy approved for cancer treatment.
- IMC-C103C, targeting MAGE-A4 for solid tumors, advancing through clinical trials.
- IMC-F106C, another TCR therapy targeting PRAME positive solid tumors, in early clinical development stages.
- IMC-I109V, aimed at treating infectious diseases, leveraging their TCR technology for a novel approach.
- Research in ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) technology, focusing on redirecting and activating T cells to recognize and kill cancer cells.
- Partnership programs with leading pharmaceutical companies to expand their TCR technology applicability and enhance their drug development pipeline.
equipe executiva do Immunocore
- Bahija JallalCEO & Executive Director
- Travis Alan CoyCFO, Executive VP & Head of Corporate Development
- Kripa RamExecutive VP & Chief Operating Officer
- John Goll IIISVP, Finance & Chief Accounting Officer
- Annelise VuidepotChief Science and Technology Officer & Milton Park Site Head
- Sean D. BuckleyVP & Chief Information Officer
- Ryan BakerVice President of Investor Relations
- Lily Margaret HepworthExecutive VP, General Counsel & Company Secretary
- Elizabeth Varki JobesChief Compliance Officer
- Sébastien DesprezVice President of Communications
Principais indicadores financeiros
Resultados divulgados pela Immunocore, em USD.
- Cap. de mercado
- 1,7 bi
- Receita (TTM)
- 430,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- -4.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 297,6 mi | -33,7 mi | -26,4 mi | |
| 248 mi | -56,3 mi | -40,8 mi | |
| 197,4 mi | -47,2 mi | -43,8 mi | |
| 144,2 mi | -42,8 mi | -43,5 mi |